{"id":41161,"date":"2025-09-11T13:47:30","date_gmt":"2025-09-11T05:47:30","guid":{"rendered":"https:\/\/flcube.com\/?p=41161"},"modified":"2025-09-11T13:47:31","modified_gmt":"2025-09-11T05:47:31","slug":"chinas-drug-evaluation-authority-issues-draft-rules-for-class-i-atmp-meetings","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=41161","title":{"rendered":"China\u2019s Drug Evaluation Authority Issues Draft Rules for Class\u202fI ATMP Meetings"},"content":{"rendered":"\n<p>The Center for Drug Evaluation (CDE), part of China\u2019s National Medical Products Administration (NMPA), published the <em>Detailed Rules for the Application and Management of Class\u202fI Meetings on Communication Regarding Advanced Therapy Medicinal Products (Draft for Public Comments)<\/em>. The draft invites public input for one month from the release date and outlines a streamlined 30\u2011day review process for key advanced\u2011therapy product communications.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-scope-of-the-new-rules\">Scope of the New Rules<\/h3>\n\n\n\n<p>The regulations apply to three distinct scenarios involving advanced therapy medicinal products (ATMPs):<\/p>\n\n\n\n<ol class=\"wp-block-list\">\n<li><strong>Breakthrough Therapy Designation<\/strong> \u2013 ATMPs that have received NMPA\u2019s Breakthrough Therapy Designation.<\/li>\n\n\n\n<li><strong>Gene\u2011Therapy Targeting Inherited Disorders<\/strong> \u2013 Gene\u2011therapy products designed to correct underlying genetic defects.<\/li>\n\n\n\n<li><strong>Pre\u2011Pivotal Communication<\/strong> \u2013 ATMPs that have completed exploratory trials and seek a meeting before pivotal\/confirmatory studies or NDA submission.<\/li>\n<\/ol>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-class-i-meeting-framework\">Class\u202fI Meeting Framework<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Classification<\/strong> \u2013 All meetings under the three scenarios are designated <strong>Class\u202fI<\/strong>.<\/li>\n\n\n\n<li><strong>Purpose<\/strong> \u2013 Accelerate regulatory dialogue, reduce lead times, and improve communication efficiency.<\/li>\n\n\n\n<li><strong>Timeline<\/strong> \u2013 Targeted 30\u2011day turnaround from application to meeting scheduling.<\/li>\n\n\n\n<li><strong>Management<\/strong> \u2013 Dedicated CDE review panels will assess applications, ensuring consistency and speed.<\/li>\n<\/ul>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-public-participation\">Public Participation<\/h3>\n\n\n\n<p>CDE\u2019s draft invites stakeholders\u2014pharmaceutical companies, biotech firms, clinical researchers, and patient advocates\u2014to submit comments within one month. Public feedback will shape final regulatory language and operational guidance.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-market-impact\">Market Impact<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>For Innovators<\/strong> \u2013 Faster access to regulatory guidance may shorten development timelines for breakthrough and gene\u2011therapy products.<\/li>\n\n\n\n<li><strong>For Investors<\/strong> \u2013 Clearer, faster communication pathways reduce risk and can accelerate time\u2011to\u2011market valuations.<\/li>\n\n\n\n<li><strong>For Patients<\/strong> \u2013 Accelerated development of ATMPs could bring innovative therapies to Chinese patients more swiftly.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/li>\n<\/ul>\n","protected":false},"excerpt":{"rendered":"<p>The Center for Drug Evaluation (CDE), part of China\u2019s National Medical Products Administration (NMPA), published&#8230;<\/p>\n","protected":false},"author":1,"featured_media":41162,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[4],"tags":[2206,14],"class_list":["post-41161","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-policy-regulatory","tag-cmde","tag-nmpa"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.5) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>China\u2019s Drug Evaluation Authority Issues Draft Rules for Class\u202fI ATMP Meetings - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"The Center for Drug Evaluation (CDE), part of China\u2019s National Medical Products Administration (NMPA), published the Detailed Rules for the Application and Management of Class\u202fI Meetings on Communication Regarding Advanced Therapy Medicinal Products (Draft for Public Comments). The draft invites public input for one month from the release date and outlines a streamlined 30\u2011day review process for key advanced\u2011therapy product communications.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=41161\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"China\u2019s Drug Evaluation Authority Issues Draft Rules for Class\u202fI ATMP Meetings\" \/>\n<meta property=\"og:description\" content=\"The Center for Drug Evaluation (CDE), part of China\u2019s National Medical Products Administration (NMPA), published the Detailed Rules for the Application and Management of Class\u202fI Meetings on Communication Regarding Advanced Therapy Medicinal Products (Draft for Public Comments). The draft invites public input for one month from the release date and outlines a streamlined 30\u2011day review process for key advanced\u2011therapy product communications.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=41161\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2025-09-11T05:47:30+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-09-11T05:47:31+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/09\/1106.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=41161#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=41161\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"China\u2019s Drug Evaluation Authority Issues Draft Rules for Class\u202fI ATMP Meetings\",\"datePublished\":\"2025-09-11T05:47:30+00:00\",\"dateModified\":\"2025-09-11T05:47:31+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=41161\"},\"wordCount\":273,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=41161#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/09\\\/1106.webp\",\"keywords\":[\"CMDE\",\"NMPA\"],\"articleSection\":[\"Policy \\\/ Regulatory\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=41161#respond\"]}],\"copyrightYear\":\"2025\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=41161\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=41161\",\"name\":\"China\u2019s Drug Evaluation Authority Issues Draft Rules for Class\u202fI ATMP Meetings - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=41161#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=41161#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/09\\\/1106.webp\",\"datePublished\":\"2025-09-11T05:47:30+00:00\",\"dateModified\":\"2025-09-11T05:47:31+00:00\",\"description\":\"The Center for Drug Evaluation (CDE), part of China\u2019s National Medical Products Administration (NMPA), published the Detailed Rules for the Application and Management of Class\u202fI Meetings on Communication Regarding Advanced Therapy Medicinal Products (Draft for Public Comments). The draft invites public input for one month from the release date and outlines a streamlined 30\u2011day review process for key advanced\u2011therapy product communications.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=41161#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=41161\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=41161#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/09\\\/1106.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/09\\\/1106.webp\",\"width\":1080,\"height\":608,\"caption\":\"China\u2019s Drug Evaluation Authority Issues Draft Rules for Class\u202fI ATMP Meetings\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=41161#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"China\u2019s Drug Evaluation Authority Issues Draft Rules for Class\u202fI ATMP Meetings\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"China\u2019s Drug Evaluation Authority Issues Draft Rules for Class\u202fI ATMP Meetings - Insight, China&#039;s Pharmaceutical Industry","description":"The Center for Drug Evaluation (CDE), part of China\u2019s National Medical Products Administration (NMPA), published the Detailed Rules for the Application and Management of Class\u202fI Meetings on Communication Regarding Advanced Therapy Medicinal Products (Draft for Public Comments). The draft invites public input for one month from the release date and outlines a streamlined 30\u2011day review process for key advanced\u2011therapy product communications.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=41161","og_locale":"en_US","og_type":"article","og_title":"China\u2019s Drug Evaluation Authority Issues Draft Rules for Class\u202fI ATMP Meetings","og_description":"The Center for Drug Evaluation (CDE), part of China\u2019s National Medical Products Administration (NMPA), published the Detailed Rules for the Application and Management of Class\u202fI Meetings on Communication Regarding Advanced Therapy Medicinal Products (Draft for Public Comments). The draft invites public input for one month from the release date and outlines a streamlined 30\u2011day review process for key advanced\u2011therapy product communications.","og_url":"https:\/\/flcube.com\/?p=41161","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2025-09-11T05:47:30+00:00","article_modified_time":"2025-09-11T05:47:31+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/09\/1106.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=41161#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=41161"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"China\u2019s Drug Evaluation Authority Issues Draft Rules for Class\u202fI ATMP Meetings","datePublished":"2025-09-11T05:47:30+00:00","dateModified":"2025-09-11T05:47:31+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=41161"},"wordCount":273,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=41161#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/09\/1106.webp","keywords":["CMDE","NMPA"],"articleSection":["Policy \/ Regulatory"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=41161#respond"]}],"copyrightYear":"2025","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=41161","url":"https:\/\/flcube.com\/?p=41161","name":"China\u2019s Drug Evaluation Authority Issues Draft Rules for Class\u202fI ATMP Meetings - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=41161#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=41161#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/09\/1106.webp","datePublished":"2025-09-11T05:47:30+00:00","dateModified":"2025-09-11T05:47:31+00:00","description":"The Center for Drug Evaluation (CDE), part of China\u2019s National Medical Products Administration (NMPA), published the Detailed Rules for the Application and Management of Class\u202fI Meetings on Communication Regarding Advanced Therapy Medicinal Products (Draft for Public Comments). The draft invites public input for one month from the release date and outlines a streamlined 30\u2011day review process for key advanced\u2011therapy product communications.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=41161#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=41161"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=41161#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/09\/1106.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/09\/1106.webp","width":1080,"height":608,"caption":"China\u2019s Drug Evaluation Authority Issues Draft Rules for Class\u202fI ATMP Meetings"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=41161#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"China\u2019s Drug Evaluation Authority Issues Draft Rules for Class\u202fI ATMP Meetings"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/09\/1106.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/41161","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=41161"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/41161\/revisions"}],"predecessor-version":[{"id":41163,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/41161\/revisions\/41163"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/41162"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=41161"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=41161"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=41161"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}